Biologics Increase Risk of Postoperative Infection

BY TIMOTHY F. KIRN
Sacramento Bureau

SAN ANTONIO — Rheumatoid arthritis patients who are on tumor necrosis factor-inhibitor therapy have a fourfold greater risk of developing deep postoperative infections, according to a Johns Hopkins University review of patients who had undergone orthopedic procedures.

The findings, although not definitive, suggest that these agents should be stopped before surgery, Jon T. Giles, M.D., said at the annual meeting of the American College of Rheumatology.

Based on each agent’s half-life, Dr. Giles recommended that etanercept be discontinued 2 weeks before surgery, infliximab 8 weeks before surgery, and adalimumab 4 weeks before surgery.

“In addition, we recommend avoidance of TNF inhibitors for 2 weeks after surgery,” he said.

Even without adding the biologics, patients with rheumatoid arthritis already have a higher risk of postoperative infection, noted Dr. Giles of Johns Hopkins University, Baltimore. Compared with a 1% rate of infection among people in the general population undergoing orthopedic procedures, infection rates among rheumatoid arthritis patients are two- to fourfold higher.

Dr. Giles’s investigation involved 91 RA patients who had undergone a bone or joint surgical procedure in a Johns Hopkins clinic during a 5-year period from the beginning of 1999. Half of those patients had large joint arthroplasty procedures, and the rest were divided between fusion or resection procedures with no implanted materials and small joint procedures.

Among the 35 patients identified to be on biologic therapy at the time of surgery, seven developed early, deep, postoperative infections, including two cases of osteomyelitis, three cases of septic arthritis, and two cases of paraspinal abscess. There were three infections among the 56 patients not taking a biologic.

Patients on TNF-inhibitor therapy had an unadjusted 4.4 odds ratio for developing infection, compared with those patients not on the biologics; after adjustment for age, gender, and disease duration, the odds ratio rose to 4.6. After adjustment for prednisone use, diabetes, and presence of rheumatoid factor, the odds ratio was 5.3.

Given the study’s small numbers, it could not be determined if the risk of infection varied by the type of surgery, site of surgery, or particular biologic agent used.

Remicade Label: Severe Hepatic Reactions Added

A small number of patients using infliximab (Remicade) have had very severe hepatic reactions, according to a revision of the package prescribing information.

In announcing the new safety information, the Food and Drug Administration and Centocor Inc. said there have been three cases reported in clinical trials.

and Centocor Inc. said there have been 35 of the package prescribing information.

hepatic reactions, according to a revision it was approved for ankylosing spondylitis.

rheumatoid arthritis patients.

creased risk of developing pneumonia, patients receiving infliximab may be at an increased risk of developing pneumonia, based on data from clinical trials data in rheumatoid arthritis patients.

Infliximab is approved for rheumatoid arthritis and Crohn’s disease; in December, it was approved for ankylosing spondylitis.

—Timothy F. Kirn

Rheumatologists prescribe EVOXAC® (cevimeline HCl) more than any other secretory agonist*

EVOXAC® first line—proven relief for the dry-mouth symptoms of Sjögren’s syndrome

Mouth-watering relief

Patients treated with EVOXAC reported significant improvement for the following end points1-3†‡:

Feeling of mouth
Dryness of mouth
Dryness of tongue

Ability to speak without drinking liquids

Ability to chew and swallow food

Ability to sleep

Safety considerations

• The most frequently reported adverse events associated with the pharmacologic action of a muscarinic agonist (>10% incidence) in clinical trials of cevimeline were: excessive sweating, nausea, rhinitis, and diarrhea. Consult the brief summary of prescribing information for other adverse events.

• Cevimeline is contraindicated in patients with uncontrolled asthma, known hypersensitivity to the drug, and in acute iritis and narrow-angle (angle-closure) glaucoma.

• Consult the brief summary of prescribing information for safety considerations concerning drug interactions, special populations, patients with a history of cardiac disease, controlled asthma, chronic bronchitis, COPD, nephrolithiasis, or cholelithiasis.

Please see accompanying brief summary of prescribing information.


† In 1 or more clinical trials, patients reported significant improvement for these secondary end points at various measurement intervals using a visual analogue scale (VAS) (p < 0.05).

‡ Statistical significance was not observed consistently for every secondary end point at each point of measurement across all studies.

For more information about EVOXAC, visit www.evoxac.com